Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programme

Simple item page
dc.contributor.authorWarrener, Lenesha
dc.contributor.authorBwogi, Josephine
dc.contributor.authorAndrews, Nick
dc.contributor.authorSamuel, Dhanraj
dc.contributor.authorKabaliisa, Theopista
dc.contributor.authorBukenya, Henry
dc.contributor.authorBrown, Kevin
dc.contributor.authorRoper, Martha H.
dc.contributor.authorFeatherstone, David A.
dc.contributor.authorBrown, David
dc.date.accessioned2022-01-20T17:38:08Z
dc.date.available2022-01-20T17:38:08Z
dc.date.issued2018
dc.description.abstractTo study the antibody response to tetanus toxoid and measles by age following vaccination in children aged 4 months to 6 years in Entebbe, Uganda. Serum samples were obtained from 113 children aged 4–15 months, at the Mother-Child Health Clinic (MCHC), Entebbe Hospital and from 203 of the 206 children aged between 12 and 75 months recruited through the Outpatients Department (OPD). Antibodies to measles were quantified by plaque reduction neutralisation test (PRNT) and with Siemens IgG EIA. VaccZyme IgG EIA was used to quantify anti-tetanus antibodies. Sera from 96 of 113 (85.0%) children attending the MCHC contained Measles PRNT titres below the protective level (120 mIU/ml). Sera from 24 of 203 (11.8%) children attending the OPD contained PRNT titres <120 mIU/ml. There was no detectable decline in anti-measles antibody concentrations between 1 and 6 years. The anti-tetanus antibody titres in all 113 children attending MCHC and in 189 of 203 (93.1%) children attending the OPD were >0.15 IU/ml by EIA, a level considered protective. The overall concentration of anti-tetanus antibody was sixfold higher in children under 12 months compared with the older children, with geometric mean concentrations of 3.15 IU/ml and 0.49 IU/ml, respectively. For each doubling in age between 4 and 64 months, the anti-tetanus antibody concentration declined by 50%. As time since the administration of the third DTP vaccination doubled, anti-tetanus antibody concentration declined by 39%. The low measles antibody prevalence in the children presenting at the MCHC is consistent with the current measles epidemiology in Uganda, where a significant number of measles cases occur in children under 1 year of age and earlier vaccination may be indicated. The consistent fall in antitetanus antibody titre over time following vaccination supports the need for further vaccine boosters at age 4–5 years as recommended by the WHO.en_US
dc.identifier.citationWarrener L et al (2018). Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programme. Epidemiology and Infection 146, 1151–1156. https://doi.org/10.1017/S0950268818000948en_US
dc.identifier.urihttps://doi.org/10.1017/S0950268818000948
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1347
dc.language.isoenen_US
dc.publisherEpidemiology and Infectionen_US
dc.subjectAntibody persistenceen_US
dc.subjectMeasles vaccinationen_US
dc.subjectTetanus toxoiden_US
dc.titleSerum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programmeen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Serum anti-tetanus and measles antibody.pdf
Size:
350.07 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences